These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9158080)

  • 1. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
    Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
    Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
    Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
    Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
    Jayo MJ; Register TC; Carlson CS
    Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
    Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
    J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
    Maturitas; 2003 Jul; 45(3):175-83. PubMed ID: 12818462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
    Heikkinen J; Vaheri R; Kainulainen P; Timonen U
    Osteoporos Int; 2000; 11(11):929-37. PubMed ID: 11193245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.
    Prior JC; Vigna YM; Wark JD; Eyre DR; Lentle BC; Li DK; Ebeling PR; Atley L
    J Bone Miner Res; 1997 Nov; 12(11):1851-63. PubMed ID: 9383690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding.
    Archer DF; Pickar JH
    Obstet Gynecol; 2000 Dec; 96(6):899-905. PubMed ID: 11084175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin.
    Xing S; Wu Y; Liu J; Xu R; Zhang Z; Wang Y
    Chin Med J (Engl); 2003 Apr; 116(4):584-7. PubMed ID: 12875727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.
    Ongphiphadhanakul B; Piaseu N; Tung SS; Chailurkit L; Rajatanavin R
    Maturitas; 2000 Feb; 34(2):179-84. PubMed ID: 10714913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group.
    Archer DF; Pickar JH; Bottiglioni F
    Obstet Gynecol; 1994 May; 83(5 Pt 1):686-92. PubMed ID: 8164926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.